News - OBI Pharma 台灣浩鼎

2016.Feb.21

未分類

Corporate

OBI Pharma Reports Topline Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer

2015.Oct.05

未分類

Corporate

OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan

2015.Aug.31

未分類

Corporate

OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016

2015.Jun.04

未分類

Corporate

Clarification about the Progressive Disease (PD) number of the OPT-822-001 Clinical Trial as reported in the Taiwan Media on 4 June 2015

2014.Dec.08

未分類

Corporate

Cancer Active Immunotherapy OBI-822 Mechanism Action

2014.Dec.08

未分類

Corporate

Introduction of OBI PHARMA, INC.’s

2014.Jul.21

未分類

Corporate

OBI Pharma Announces Completion of Patient Enrollment in Phase 2/Phase 3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer

2014.Jan.15

未分類

Corporate

Award & Certification

OBI Pharma, Inc. won Taiwan “Venture Capital Star” The Best Investment Award

2013.Oct.08

未分類

Corporate

OBI Pharma Announces NT$ 1.5 Billion Capital Infusion

2013.Jul.26

未分類

Corporate

Award & Certification

OBI Pharma Wins the "Greatest Potential Award" at the 2013 Outstanding Biotech Awards

Announcements

Latest announcements

Events

Latest events